


## IRAK inhibitor 3

Cat. No.:	HY-13277		
CAS No.:	1012343-93-9		
Molecular Formula:	C <sub>21</sub> H <sub>21</sub> N <sub>5</sub> O <sub>4</sub> S		
Molecular Weight:	439.49		
Target:	IRAK		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 13 mg/mL (29.58 mM; Need ultrasonic and warming)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.2754 mL	11.3768 mL	22.7536 mL
5 mM	0.4551 mL	2.2754 mL	4.5507 mL
10 mM	0.2275 mL	1.1377 mL	2.2754 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

IRAK inhibitor 3 is an interleukin-1 (IL-1) receptor-associated kinase (IRAK) kinase modulator extracted from patent WO2008030579 A2.

#### IC<sub>50</sub> & Target

IRAK<sup>[1]</sup>

#### In Vitro

IRAK inhibitor 3 is an IRAK modulator, which can be used for treating an inflammatory condition, cell proliferative disorder, immune disorder<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### PROTOCOL

#### Kinase Assay <sup>[1]</sup>

5 μL of a solution of IRAK inhibitor 3 at a concentration of 50 μM or less in 1% (v/v) DMSO is added to the wells of a 96-well area Black Polystyrene plates. The final concentrations in the reaction well are 10 μM ATP, 0.5 μM IRAK4 CH373, 1.6 μM IRAK1

---

peptide, 1 mM MgCl<sub>2</sub>, 2 mM DTT, 5 mM MnCl<sub>2</sub>, 0.01 % BSA, and 0.01 % Tween-20. The volume of the reaction is 45 μL. The reaction mixture is incubated at room temperature for 30 minutes and stopped with the addition of 5 μL of 100 mM EDTA<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

- Neurotherapeutics. 2021 May 10.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Thomas Durand-Reville, et al. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder. WO 2008030579 A2.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA